中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

117 records (took 0.022 seconds)

    ANTI-BACTERIAL AGENTS AND THEIR USE IN THERAPY
    63.
    发明申请
    ANTI-BACTERIAL AGENTS AND THEIR USE IN THERAPY 审中-公开

    公开(公告)号：US20180141977A1

    公开(公告)日：2018-05-24

    申请号：US15570837

    申请日：2016-05-06

    Applicant: Norwegian University of Science and Technology (NTNU)

    Inventor： Marit OTTERLEI ,  Siri BACHKE

    IPC: C07K14/00 ,  A61K38/17 ,  A61K47/50 ,  C12N5/078 ,  A61L27/22 ,  A61L9/20

    CPC classification number: C07K14/003 ,  A61K38/1709 ,  A61K47/50 ,  A61L9/20 ,  A61L27/227 ,  C07K14/4738 ,  C12N5/0634 ,  Y02A50/402 ,  Y02A50/475 ,  Y02A50/478 ,  Y02A50/479 ,  Y02A50/481

    Abstract: The present invention provides an agent, or a composition containing an agent, for use in treating or preventing a bacterial infection in a subject, wherein said agent comprises: (i) an oligopeptidic compound comprising a PCNA interacting motif and a domain that facilitates the cellular uptake of said compound, wherein the PCNA interacting motif is X1X2X3X4X5X6 (SEQ ID NO: 1) and wherein: X1 is a basic amino acid; X2 is an aromatic amino acid; X3 is an aromatic amino acid or a hydrophobic amino acid that has an R group comprising at least three carbon atoms; X4 is an uncharged amino acid other than an aromatic amino acid, Glycine (G) and Proline (P); X5 is any amino acid other than an acidic amino acid or an aromatic amino acid; and X6 is any amino acid other than an acidic amino acid or an aromatic amino add, preferably a basic amino add or Proline (P), wherein when X3 is not an aromatic amino acid, X5 is not lysine (K) and X6 is a basic amino acid or Proline (P): or (ii) a nucleic acid molecule comprising a sequence encoding the oligopeptidic compound of (i). In certain aspects the agent and composition of the invention may be used as single agents, in other aspects of the invention the agents and composition may be used in conjunction with one or more addition active agents, such as antibiotics, or in combination with UV radiation.

    Model Generation for Drug Determination
    65.
    发明申请
    Model Generation for Drug Determination 审中-公开

    公开(公告)号：US20170103183A1

    公开(公告)日：2017-04-13

    申请号：US15291341

    申请日：2016-10-12

    Applicant: NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY

    Inventor： Åsmund Flobak

    IPC: G06F19/00 ,  A61B5/00

    CPC classification number: A61B5/4848 ,  A61B5/4839 ,  G16B5/00 ,  G16C20/30 ,  G16H50/50

    Abstract: Disclosed herein is a computer-implemented method for simulating a response of a drug, or a combination of drugs, being used for the treatment of a disease, the method comprising a computing device performing the steps of: generating one or more models of cell responses in a biological network of cellular processes, wherein each model is a self-contained logical model that comprises a network topology with nodes, edges between nodes and parameters of the nodes for modelling obtained state data of a plurality of biological signalling entities of one or more diseased cells, wherein generating each model comprises automatically determining logical rules that define at least the parameters of the nodes such that an attractor of the model substantially corresponds to said obtained state data of the plurality of biological signalling entities of one or more diseased cells; for each of the one or more models, simulating the effect of a drug, or a combination of drugs, by determining an output of the generated model when the states of one or more nodes of the model are changed in accordance with the expected effect of the drug, or the combination of drugs, on one or more of said biological signalling entities; and determining a drug, or a combination of drugs, for the treatment of the one or more diseased cells in dependence on the outputs of the one or more models. Advantageously, a fast and inexpensive technique is provided for determining drug(s), or combinations of drugs, for the treatment of the disease.

    BIOFEEDBACK SYSTEM
    69.
    发明公开
    BIOFEEDBACK SYSTEM 审中-公开

    公开(公告)号：US20230172540A1

    公开(公告)日：2023-06-08

    申请号：US18000695

    申请日：2021-02-03

    Applicant: NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY (NTNU)

    Inventor： Marcus Aleksander ENGEBRETSEN ,  Anker STUBBERUD ,  Mattias LINDE ,  Alexander OLSEN ,  Erling TRONVIK ,  Herindrasana RAMAMPIARO

    IPC: A61B5/00

    CPC classification number: A61B5/486 ,  A61B5/4824 ,  A61B5/4836

    Abstract: A biofeedback system for headache patients comprises: a sensor system (2) for obtaining and transmitting data indicative of a plurality of physiological parameters of the patient, a personal computing device (4) arranged to receive data from the sensor system (2) and to interact with the patient via a user interface of the personal computing device (4), and a computer-implemented biofeedback agent (6). The sensor system (2) is configured for measurement of the physiological parameters of the patient, wherein the physiological parameters include at least two of muscle tension, body temperature, heart rate and heart rate variability. The personal computing device (4) together with the biofeedback agent (6) are configured to carry out the following steps: obtain data indicative of the physiological parameters from the sensor system (2); instruct the patient to control the physiological parameters; determine baseline levels for each of the physiological parameters; derive a score for each of the physiological parameters relative to the baseline levels, wherein the score increases in reaction to control of the respective physiological parameter; and use a weighting system to determine a weighting for the score associated with each of the physiological parameters and present a total score to the patient via the user interface, the total score consisting of a combination of the weighted scores, wherein the weighting system gives a higher weighting to the score for the physiological parameter that the patient most successfully controls and a lower weighting to the score for the physiological parameter that the patient least successfully controls.

Patent Agency Ranking